Corcept Therapeutics Inc (CORT) reports increased revenue and expanding market opportunities, despite facing operational ...

Discover insights from Corcept Therapeutics' Q1 2025 earnings call: revenue growth, relacorilant's FDA review, and its strategic outlook ...

Biopharma company Corcept Therapeutics (NASDAQ:CORT) in Q1 CY2025, but sales rose 7.1% year on year to $157.2 million. On the ...

Corcept attributed the revenue shortfall to supply chain issues at its specialty pharmacy vendor early in the quarter, which impacted its ability to fulfill a surge in demand. The company noted that ...

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of ...

The Company expects to submit a New Drug Application to the Food and Drug Administration in the third quarter of 2025.

For the past 7 years, Bayer has shelled out billions of dollars in lawsuits brought by people claiming they developed cancer after exposure to its glyphosate-containing weed killers, including its ...

A panelist discusses how education and cost are key challenges in ensuring comprehensive molecular testing is performed in a ...

A panelist discusses how multiple molecular biomarkers beyond BRCA and homologous recombination deficiency (HRD) testing are ...

The FDA has granted fast track designation to INX-315 for the treatment of CCNE1-amplified, platinum-resistant/refractory ovarian cancer.

We recently published a list of Billionaire Jim Simons’ RenTech’s 10 Small-Cap Stock Picks with Huge Upside Potential.